Specialist Updates 
Oncology

Safe to stop immunotherapy at two years in advanced NSCLC: study

Results should reassure patients with progression-free advanced disease, say doctors.
0
21 June 2023
Save

Patients who are progression-free on immunotherapy for advanced or metastatic lung cancer can safely discontinue therapy after two years, US oncologists report.

Despite doctors’ “substantial hesitation” to cease immune checkpoint inhibitor (ICI) therapy, the researchers found no overall survival benefit from indefinite treatment.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .